
Reset all filters
01 11Vytorin
02 4Zocor
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 183
2019 Revenue in Millions : 285
Growth (%) : -36
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 65
2020 Revenue in Millions : 77
Growth (%) : -16
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 164
2020 Revenue in Millions : 182
Growth (%) : -10
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 130
2021 Revenue in Millions : 164
Growth (%) : -21
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 129
2022 Revenue in Millions : 130
Growth (%) : -1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 108
2023 Revenue in Millions : 129
Growth (%) : -16
Main Therapeutic Indication : Cardiovascular
Currency : USD
2015 Revenue in Millions : 1,516
2014 Revenue in Millions : 1,251
Growth (%) : -17%
Main Therapeutic Indication : Cardiovascular
Currency : USD
2014 Revenue in Millions : -7.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Antihypertensives
Currency : USD
2015 Revenue in Millions : 258
2014 Revenue in Millions : 217
Growth (%) : -16%
Main Therapeutic Indication : Antihypertensives
Currency : USD
2014 Revenue in Millions : -14.30%
2013 Revenue in Millions :
Growth (%) :